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Introduction
Breast cancer is the most common cancer in women worldwide, with prevalence predicted to further increase 
in the future, representing a tremendous medical and socioeconomic burden (1). After treatment of  the 
primary tumor, metastases often occur years or even decades later (1). Bone is a premier site for breast can-
cer metastases, and about 70% of  breast cancer patients with advanced disease experience osteolytic bone 
metastases, a stage at which the disease is incurable (2). Osteolytic metastases often cause skeletal-related 
events (SREs), including pathological fractures and pain, that require palliative interventions (3, 4).
Destruction of  the bone tissue in breast cancer–induced osteolytic disease occurs due to an increased 
number and activity of  bone-resorbing osteoclasts (5). Osteoclasts are activated in a direct or indirect 
manner by cancer- and microenvironment-derived cytokines, including parathyroid hormone–related 
peptide (PTHrP), receptor activator of  NF-κB ligand (RANKL), and interleukins. Upon activation of  
bone resorption, matrix-derived growth factors and in particular TGF-β further enhance tumor growth 
and osteoclast activity, constituting a vicious cycle of  bone metastasis (5). While it is firmly established 
that breast cancer cell– and matrix-derived growth factors stimulate osteoclast activity, evidence exists 
that breast cancer cells also provide molecular cues that suppress osteoblast function (6). Thus, it can 
be hypothesized that restoring osteoblast function might ameliorate metastatic bone disease. Neverthe-
less, the exact role of  bone-forming osteoblasts in the context of  breast cancer metastases–mediated bone 
destruction and their potential use for pharmacological treatment is not yet elucidated.
In addition to chemotherapy and radiation therapy, patients with osteolytic metastases are treated 
with antiresorptive drugs such as bisphosphonates or an antibody against RANKL (denosumab; XGEVA, 
Amgen) that efficiently restrict osteoclast activity and therefore the progression of  bone destruction (7). 
Breast cancer bone metastases often cause a debilitating incurable condition with osteolytic 
lesions, muscle weakness, and a high mortality. Current treatment comprises chemotherapy, 
irradiation, surgery, and antiresorptive drugs that restrict but do not revert bone destruction. In 
hormone receptor–negative breast cancer cell lines and human breast cancer tissue, we identified 
the expression of sclerostin, a soluble Wnt inhibitor that represses osteoblast differentiation 
and bone formation. In mice with breast cancer bone metastases, pharmacological inhibition of 
sclerostin using an anti-sclerostin antibody (Scl-Ab) reduced the metastatic burden. Furthermore, 
sclerostin inhibition prevented cancer-induced bone destruction by augmenting osteoblast-
mediated bone formation and by reducing osteoclast-dependent bone resorption. During advanced 
disease, NF-κB and p38 signaling was increased in muscles in a TGF-β1–dependent manner, causing 
muscle fiber atrophy, muscle weakness, and tissue regeneration with an increase in Pax7-positive 
satellite cells. Scl-Ab treatment restored NF-κB and p38 signaling, the abundance of Pax7-positive 
cells, and muscle function. These effects improved the health and expanded the life span of cancer-
bearing mice. Together, these results demonstrate that pharmacological inhibition of sclerostin 
reduces bone metastatic burden and muscle weakness, with a prolongation of survival time. This 
might provide novel options for treating musculoskeletal complications in breast cancer patients.
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Due to advances in surgery, adjuvant chemotherapy, hormone receptor blocking drugs, and antiresorptive 
therapies, the survival time of  patients has been greatly prolonged (8). However, overall morbidity and mor-
tality are still very high, particularly once SREs occur (8). Furthermore, the disease remains irreversible, 
and osteolytic lesions persist (8).
Since antiresorptive drugs cannot revert osteolytic lesions, augmenting osteoblast function has been 
proposed as a potential approach to restore bone integrity in the context of  metastasis-induced osteolytic 
lesions (9). To date, only 2 bone anabolic drugs are available in the clinic for the treatment of  osteopo-
rosis, a debilitating disease that leads to loss of  bone mass and ultimately fragility fractures. Intermittent 
administration of  a recombinant fragment of  parathyroid hormone (PTH 1-34; teriparatide; Forteo/
Forsteo, Eli Lilly and Co.) or of  a PTH-related peptide analog (PTHrP 1-34; abaloparatide; Tymlos, 
Radius) increase osteoblast-mediated bone formation and bone mass but are not approved for use in 
cancer patients (6). Thus, there is currently no osteoblast-targeting drug available that could be used for 
the treatment of  cancer-related bone disease.
Osteoblast differentiation and function is regulated by a network of  transcription factors and signaling 
pathways (10). Canonical Wnt signaling is among the most prominent pathways promoting osteoblast 
differentiation, function, and bone formation (11). Activation of  the canonical Wnt pathway occurs upon 
binding of  Wnt ligands to low-density lipoprotein receptor–related proteins 5 and 6 (Lrp5/6), which form 
a complex with frizzled-related proteins. Sclerostin is a soluble Wnt antagonist that prevents binding of  
Wnt ligands to Lrp5/6 and therefore the activation of  the pathway and ultimately osteoblast-mediated 
bone formation (11). Due to its strong inhibitory effect on Wnt signaling and pharmacological accessibil-
ity, sclerostin has emerged as a promising drug target, and anti-sclerostin antibodies (Scl-Ab) have been 
developed to increase bone formation and bone mineral density (BMD) in the context of  postmenopausal 
osteoporosis (12, 13). In clinical trials, treatment of  women with postmenopausal osteoporosis with Scl-Ab 
(romosozumab; Evenity, Amgen/UCB) increased bone formation, while bone resorption was decreased, 
leading to an increase in BMD and a reduction of  the fracture rate at several sites, including the hip and 
spine (13, 14). Recently, romosozumab was approved in Japan and in the United States for the treatment 
of  severe postmenopausal osteoporosis, and it is expected to become available in the Europe later in 2019. 
Thus far, activation of  the canonical Wnt signaling pathway in the skeleton has not caused any malignant 
side effect, either in preclinical animal models or by genetic or pharmacological means in humans, demon-
strating the overall safety of  this approach in the musculoskeletal system. The strong effect of  Wnt activa-
tion on increasing BMD and decreasing the fracture rate is also of  interest in the context of  bone fragility 
syndromes other than osteoporosis. For instance, osteogenesis imperfecta (OI) is often caused by mutations 
in the gene encoding collagen type 1, leading to brittle bones and fractures (15). In this context, another 
Scl-Ab (BPS-804, setrusumab; Mereo BioPharma) is currently being investigated in clinical trials for the 
treatment of  patients with OI (16).
In breast cancer patients, SREs are often associated with muscle weakness, a debilitating condition that 
decreases mobility, well-being, and life quality of breast cancer patients (17, 18). The disease mechanisms under-
lying cancer-associated muscle weakness are largely unknown, and no therapy is available to date (17, 18). Thus, 
novel therapeutic approaches targeting breast cancer bone metastases and muscle weakness are urgently needed.
Here we report that metastatic breast cancer cells secrete sclerostin, thereby inhibiting canonical Wnt 
signaling in osteoblasts and osteoblast differentiation, indicating that breast cancer cells might impair bone 
formation while promoting metastases and bone resorption. Treatment of  bone metastases–bearing female 
mice with Scl-Ab (setrusumab) alleviated tumor growth in bone and bone destruction without increasing 
metastases at other sites. Surprisingly, Scl-Ab treatment protected from cancer-induced muscle fiber atro-
phy and loss of  muscle function in tumor-bearing mice and prolonged the life span of  these animals. These 
findings reveal that therapeutic inhibition of  sclerostin reduces breast cancer-induced bone metastases and 
muscle weakness in mice, indicating its potential as a novel therapeutic option for breast cancer patients.
Results
Breast cancer cell–derived sclerostin inhibits Wnt signaling in osteoblasts. To address the hypothesis that metastatic 
breast cancer cells impair osteoblast differentiation, we collected conditioned medium from MDA-MB-231 
metastatic breast cancer cells and differentiated primary calvarial cells into osteoblasts in the presence or 
absence of  medium that had been conditioned by breast cancer cells. In support of  our hypothesis, condi-
tioned medium inhibited osteoblast differentiation and matrix mineralization, demonstrated by reduced 
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expression of  the osteoblast marker genes Runx2 and Ocn and weaker alizarin red S staining (Figure 1, A 
and B). Furthermore, using a TOPflash reporter gene assay, we determined that cancer cell–conditioned 
medium suppressed the activity of  the canonical Wnt signaling pathway in osteoblasts in a dose-dependent 
manner (Figure 1C). These findings indicate that metastatic breast cancer cells may secrete factors that 
inhibit canonical Wnt signaling in osteoblasts in a paracrine fashion.
Breast cancer cells have been shown to express Dickkopf  1 (Dkk1), a soluble antagonist of  canonical 
Wnt signaling. However, antagonizing cancer cell–derived Dkk1 did not fully restore the activity of  the 
Wnt pathway (19), suggesting that additional mechanisms might exist. Indeed, expression analysis revealed 
significantly higher expression of  the Wnt inhibitor sclerostin in metastatic MDA-MB-231 breast cancer 
cells compared with nonmetastatic MCF-7 breast cancer cells (Figure 1D). To determine whether sclerostin 
expression is a general feature of  breast cancer cells, we performed an in silico analysis using the EMBL-
EBI Expression Atlas (20). In addition to cells of  the MDA-MB-231 cell line, expression of  sclerostin was 
found in cells of  the SUM159PT, CAL51, HCC 1187, HCC 1197, HCC 1395, HCC 1806, and KPL-4 
breast cancer cell lines. Interestingly, 6 of  these cell lines (SUM159PT, CAL51, HCC 1187, HCC 1197, 
HCC 1395, and HCC 1806) express neither the estrogen receptor (ER) nor the progesterone receptor (PR) 
and do not bear an amplification of  the HER-2/Neu gene (referred to as triple-negative breast cancer cells) 
(21, 22). Furthermore, although KPL-4 cells have a HER-2/Neu amplification, they do not express the ER 
or the PR (23), suggesting that sclerostin expression is a common feature of  hormone receptor–negative 
breast cancer cells. To address the question of  whether sclerostin is expressed in primary breast cancer 
tissue from patients, we quantified sclerostin expression in tissue biopsies obtained from 48 breast cancer 
patients and from 4 healthy individuals. While sclerostin expression was not detected in healthy breast 
tissue, 21% of  primary breast cancers expressed sclerostin (Figure 1E). Interestingly, 56% of  triple-negative 
breast cancer tissues and 43% of  ER-negative and PR-negative breast cancer tissues expressed sclerostin 
(Figure 1E). Furthermore, 2 of  3 (66 %) metastatic breast cancers with unknown receptor status were posi-
tive for sclerostin expression. Tumors expressing either the ER or the PR or both receptors did not express 
sclerostin (data not shown). To determine whether sclerostin expression is a specific feature of  breast cancer 
or if  it is also expressed by other types of  cancer, we analyzed sclerostin expression in human colon (n = 9), 
kidney (n = 9), liver (n = 9), lung (n = 9), prostate (n = 9), ovary (n = 9), and thyroid (n = 9) cancer biopsies 
and the respective healthy tissue. Sclerostin expression was detected in 2 colon (22%), 1 ovary (11%), and 2 
lung (22%) cancer tissues, suggesting that although sclerostin expression is not specific to breast cancer, it is 
not a general oncogenic feature of  all types of  cancer (Table 1).
To investigate whether breast cancer cell–derived sclerostin reduces Wnt signaling activity in osteo-
blasts, we restricted sclerostin expression in MDA-MB-231 cells using 3 different siRNAs designed to target 
SOST mRNA (Supplemental Figure 1, A and B). Next, conditioned medium was obtained from MDA-
MB-231 cells transfected with scrambled control siRNA or siRNA targeting SOST mRNA. Indeed, antago-
nizing sclerostin expression in metastatic breast cancer cells partially but significantly restored the impaired 
Wnt signaling activity in calvarial osteoblasts (Figure 1F).
Sclerostin inhibits the activation of  the canonical Wnt signaling pathway in osteoblasts by binding to 
the first β-propeller domain of  the extracellular region of  the LRP5 receptor (24). Heterozygous missense 
mutations (G171V and A214V) within this domain of  LRP5 cause a high bone mass phenotype in patients 
and in mice due to reduced binding of  sclerostin (25, 26). To determine whether cancer cell–derived scle-
rostin inhibits Wnt activity in osteoblasts through Lrp5, we obtained osteoblasts from genetically modified 
mice heterozygous for the Lrp5 mutation G171V. In support of  our hypothesis, osteoblasts bearing a mutant 
Lrp5 with a disabled sclerostin binding site were resistant to breast cancer–mediated repression of  Wnt sig-
naling (Figure 1G). These data suggest that breast cancer cells impair osteoblast differentiation, at least in 
part, by a sclerostin/Lrp5-mediated inhibition of  the canonical Wnt signaling pathway.
Pharmacological inhibition of  sclerostin reduces bone metastatic burden and prolongs survival time. Given the 
negative effect of  cancer-derived sclerostin on osteoblasts, we hypothesized that inhibition of  scleros-
tin and subsequent activation of  osteoblast function might protect from the progression of  metastatic 
bone disease. To investigate the therapeutic potential of  Scl-Ab treatment in breast cancer–induced bone 
destruction, an in vivo metastasis model was used in which MDA-MB-231 breast cancer cells stably 
expressing the luciferase gene (MDA-MB-231-luc) were inoculated by cardiac injection into 8-week-old 
female SCID mice. To recapitulate the clinical situation of  breast cancer patients, bone metastases were 
allowed to form in mice prior to treatment. Two weeks after breast cancer cell injection, micrometastases 
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Figure 1. Breast cancer–derived sclerostin inhibits Wnt signaling in osteoblasts. (A and B) Calvarial cells were differentiated into osteoblasts in the 
presence of control medium or cancer-conditioned medium (CM) collected from MDA-MB-231 metastatic breast cancer cells. Osteoblast differen-
tiation was determined by quantification of Runx2 and osteocalcin (Ocn) gene expression (A) and by alizarin red S staining (B) (n = 4 independent 
experiments). (C) Calvarial osteoblasts were cultured in the presence of the indicated amount of MDA-MB-231–derived CM. Wnt signaling activity was 
determined by TOPflash reporter assay (n = 4 independent experiments). (D) Sclerostin mRNA expression was quantified in nonmetastatic MCF-7 and 
metastatic MDA-MB-231 breast cancer cells by qRT-PCR (n = 6 independent experiments). (E) SOST mRNA expression was analyzed in breast cancer 
tissue from 48 patients. Proportion of sclerostin-positive and sclerostin-negative tissue samples is shown for all patients and for triple-negative 
(ER–, PR–, HER–) and in hormone receptor–negative (ER–, PR–, HER+) patients. All, n = 48; ER–, PR–, HER-, n = 9; ER–, HER–, HER+, n = 7. (F) Wnt 
signaling activity in calvarial osteoblasts cultured with control medium or with CM from MDA-MB-231 cells transfected with scrambled control siRNA 
(si-Ctrl CM) or siRNA against sclerostin (si-Sclerostin CM) (n = 6 independent experiments). (G) Wnt signaling activity in calvarial osteoblasts isolated 
from mice heterozygous for the Lrp5 mutation G171V (Lrp5-G171V+/T) and from control littermates (Lrp5-G171V+/+) stimulated with control medium or 
cancer CM (n = 4 independent experiments). Data are presented as mean ± SEM. Two-tailed Student’s t test was used to compare 2 groups (A and D), 
and ANOVA followed by Tukey’s post hoc analysis was used to compare 3 or more groups (C, F, and G); *P < 0.05, **P < 0.01, ***P < 0.001. 
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were detected in the long bones by bioluminescence imaging, and mice were randomized into 2 treatment 
arms. One group was treated with Scl-Ab (100 mg/kg), while the other group received vehicle control 
(50 μl/10g) i.v. once a week for 4 weeks. Non-cancer-bearing mice without treatment, or with vehicle or 
Scl-Ab treatment served as healthy controls. Weekly bioluminescence imaging of  cancer-bearing mice 
revealed progressive growth of  bone metastases in vehicle-treated mice (Figure 2, A and B). Although 
metastases also developed in mice that received Scl-Ab, tumor growth in bones was significantly reduced 
compared with vehicle-treated controls (Figure 2, A and B). The reduced tumor growth was confirmed 
by histological analyses of  metastasis area in tibiae (Figure 2, C and D) and in the femur (Supplemental 
Figure 2A) of  cancer-bearing mice. To evaluate the potential effects of  Scl-Ab treatment on cancer cell 
relocation and metastasis formation at other sites, several organs including lung, liver, and brain were 
imaged by ex vivo bioluminescence after sacrifice (data not shown). Furthermore, expression of  HLA was 
determined by quantitative PCR (qRT-PCR) and immunohistochemistry in the brain and lung, which are 
the most common sites of  breast cancer metastases after bone. Importantly, inhibition of  sclerostin did not 
change the abundance of  breast cancer cells at extraskeletal sites such as lung and brain (Figure 2, E and 
F, and Supplemental Figure 2B), indicating that Scl-Ab treatment of  mice with bone metastases does not 
cause breast cancer cell dissemination into other organs. Due to the strong reduction of  bone metastatic 
burden, we hypothesized that Scl-Ab treatment might be beneficial for the overall life span. Indeed, Scl-Ab 
treatment significantly prolonged the survival time of  breast cancer–bearing mice (Figure 2G).
Sclerostin antibody treatment protects from breast cancer–induced bone destruction. To test the hypothesis 
that inhibition of  sclerostin might be a therapeutic approach to prevent bone destruction or to restore 
bone integrity in the context of  breast cancer-mediated bone destruction, bone mass of  mice with and 
without bone metastases was quantified by microcomputed tomography (μCT). Consistent with previ-
ous reports (27), Scl-Ab treatment of  non-tumor-bearing mice increased trabecular bone mass of  the 
distal femur (Supplemental Figure 3, A and B) and of  the proximal tibia (Supplemental Figure 3, C 
and D), as well as cortical thickness of  the femur midshaft (Supplemental Figure 3, E and F). In mice 
with bone metastases, Scl-Ab treatment protected from breast cancer–induced osteolytic lesions and 
subsequent loss of  bone mass of  the distal femur (Figure 3A) and of  the proximal tibia (Figure 3B). 
Furthermore, histological analyses of  the proximal tibia revealed a significantly reduced bone forma-
tion rate and bone mass in cancer-bearing vehicle-treated mice compared with healthy vehicle-treated 
control animals (Figure 3, C–E). Intriguingly, Scl-Ab treatment of  mice with bone metastases increased 
both bone mass and bone formation to the level of  healthy Scl-Ab–treated mice (Figure 3, D and E). 
Detailed histomorphometric analysis of  the bone surfaces nearby metastases revealed that the presence 
Table 1. Sclerostin expression in different cancers
Cancer type Total number Sclerostin-positive Sclerostin-negative
Adenocarcinoma of colon 9 2 (22 %) 7 (78%)
Carcinoma of kidney, renal cell 9 0 9 (100%)
Carcinoma of liver (all) 9 0 9 (100%)
    Hepatocellular 8 0 8
    Cholangiocarcinoma of liver 1 0 1
Carcinoma of lung (all) 9 2 (22%) 7 (78%)
    Adenocarcinoma of lung 2 0 2
    Squamous cell carcinoma 5 1 4
   Non-small cell carcinoma 2 1 1
Ovary cancer (all) 9 1 (11%) 8 (89%)
    Tumor of ovary, borderline 2 0 2
    Adenocarcinoma of ovary 7 1 6
Prostate (all) 9 0 9 (100%)
    Hyperplasia of prostate 6 0 6
    Prostatitis 2 0 2
    Adenocarcinoma of prostate 1 0 1
Carcinoma of thyroid 9 0 9 (100%)
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of  breast cancer cells blunted bone formation in vehicle-treated mice, which was significantly restored 
by Scl-Ab treatment (Figure 3, F and G). These results suggest that Scl-Ab prevents bone loss in the 
context of  bone metastases at least in part by restoring breast cancer–inhibited bone formation at the 
bone-tumor interface.
To further analyze the mode of  action of  Scl-Ab in mice with breast cancer bone metastases, ami-
no propeptide of  type I collagen (P1NP) and tartrate-resistant acid phosphatase 5b (TRAP5b) were 
measured in the serum of  cancer-bearing mice as biomarkers for bone formation and bone resorption, 
respectively. While the P1NP serum concentration was higher in Scl-Ab–treated mice, the serum con-
centration of  TRAP5b was decreased compared with vehicle-treated animals, suggesting that Scl-Ab 
treatment activates bone formation and reduces bone resorption (Supplemental Figure 4, A and B). 
This dual mode of  action has been consistently reported in the context of  the treatment of  post-
menopausal osteoporosis (13, 14). To further investigate this finding at a cellular level, parameters 
of  osteoblasts and osteoclasts were quantified in cancer-bearing mice. As expected, the number and 
size of  bone-forming osteoblasts were significantly increased in Scl-Ab–treated cancer-bearing mice 
compared with vehicle-treated control animals (Figure 3, H and I). Furthermore, the number and 
size of  bone-resorbing osteoclasts were strongly reduced in response to Scl-Ab treatment (Figure 3, 
J and K, and Supplemental Figure 4C), suggesting that the increase in bone mass was due to a con-
comitant increase in bone formation and a reduction in bone resorption. Together, these data strongly 
indicate that Scl-Ab treatment not only increases bone mass through its anabolic action by restoring 
the tumor-induced impairment of  osteoblast function, but also reduces the breast cancer–mediated 
increase in osteoclast activity, thereby reverting osteolytic disease.
Inhibition of  sclerostin prevents breast cancer–induced loss of  muscle function. Patients with bone metastases 
often experience muscle weakness (17, 18). Similarly, mice with breast cancer–induced metastatic bone 
disease have a reduced ex vivo muscle contractility compared with healthy animals (Figure 4A) (17). Given 
the beneficial effect of  Scl-Ab in reducing tumor burden and bone destruction, we postulated that inhibi-
tion of  sclerostin might also affect muscle function. To test this hypothesis, we analyzed the specific muscle 
force and endurance of  the extensor digitorum longus (EDL) muscles of  healthy mice and of  mice with 
bone metastases treated with Scl-Ab or vehicle control. Although Scl-Ab treatment increased bone mass 
in healthy mice (Figure 3, C and D, and Supplemental Figure 3), muscle function was not altered in these 
animals (Figure 4A). In contrast, Scl-Ab treatment of  mice bearing bone metastases protected from can-
cer-induced muscle weakness, as determined by quantification of  specific muscle force (Figure 4A) and 
endurance (Figure 4B). To better understand the disease mechanism of  the altered muscle function, tibialis 
anterior (TA) muscles were stained for succinate dehydrogenase and the cross-sectional area (CSA) of  
oxidative and nonoxidative fibers was quantified. Consistent with an unchanged muscle function, Scl-Ab 
treatment of  healthy mice did not affect the CSA of  either oxidative nor nonoxidative muscle fibers (Figure 
4, C and D). Interestingly, bone metastases caused a significant reduction in CSA, which was fully restored 
by Scl-Ab treatment (Figure 4, C and D). Since oxidative muscle fibers were affected in cancer-bearing 
mice (Figure 4D), it appears likely that metastatic bone disease may cause oxidative stress and muscle fiber 
atrophy in skeletal muscles, which is prevented by treatment with Scl-Ab.
Antagonizing sclerostin reverses breast cancer–induced increase in NF-κB signaling. To further elucidate 
the molecular mechanisms underlying the effect of  Scl-Ab on skeletal muscles of  cancer-bearing mice, 
we investigated various signaling pathways involved in oxidative stress. Western blot analysis revealed 
increased phosphorylation of  p38, ERK1/2, and STAT3 in gastrocnemius (GAS) muscle of  cancer-bear-
ing mice compared with healthy control animals (Figure 5A and Supplemental Figure 5A). Interest-
ingly, the cancer-induced phosphorylation of  p38 was reversed in the muscles of  Scl-Ab–treated ani-
mals (Figure 5A). Since activation of  the NF-κB pathway has been shown to be a critical component 
of  skeletal muscle atrophy (28), we investigated whether NF-κB signaling is also implicated in breast 
cancer–induced bone metastases. Under steady-state conditions, NF-κB is sequestered in the cytoplasm 
through interaction with members of  the inhibitor of  κB (IκB) family of  proteins. Upon activation, the 
IKK complex, which contains the IκB kinases IKKα and IKKβ, phosphorylates the IκB proteins, there-
by targeting them to ubiquitination and proteasomal degradation (28). Interestingly, IKKα and IKKβ 
were strongly phosphorylated in the muscles of  cancer-bearing mice treated with vehicle compared with 
healthy animals. Furthermore, phosphorylation of  the NF-κB subunit p65 was strongly increased in 
cancer-bearing mice, indicating activated NF-κB signaling. Phosphorylation of  IKKα, IKKβ, and p65 
7insight.jci.org   https://doi.org/10.1172/jci.insight.125543
R E S E A R C H  A R T I C L E
was greatly reduced by Scl-Ab treatment (Figure 5A), suggesting that the presence of  breast cancer bone 
metastases activates the p38/NF-κB signaling cascade, which is attenuated by inhibition of  sclerostin.
To determine whether sclerostin directly activates the p38/NF-κB signaling pathway in myoblasts, we 
stimulated C2C12 myoblasts with recombinant sclerostin. Sclerostin treatment did not induce phosphor-
ylation of  p38 or the components of  the NF-κB pathway (Supplemental Figure 5B and data not shown), 
suggesting that the pathway is activated indirectly by cytokines present in the metastatic microenvironment. 
Figure 2. Pharmacological inhibition of sclerostin reduces bone metastatic burden in mice. MDA-MB-231 breast cancer cells stably expressing the lucifer-
ase gene were injected into the left ventricle of 8-week-old female immune-compromised SCID mice. Micrometastases were detected 2 weeks after breast 
cancer cell injection by bioluminescence imaging (BLI). Mice were randomized and received either vehicle (n = 8) or anti-sclerostin antibody (Scl-Ab; n = 8) 
once a week for 4 weeks. (A and B) Tumor growth in bone was visualized after 4 weeks of treatment (A) and quantified (B) by BLI. Values are represented 
in a log10 scale. (C and D) Quantification of the metastasis area (C) in the tibia (D) of cancer-bearing mice treated with vehicle (n = 16 tibiae) or Scl-Ab (n = 16 
tibiae) using histological sections. Scale bar: 1 mm. (E and F) Quantification of human leukocyte antigen (HLA) mRNA expression in the lung (E) and brain 
(F) by qRT-PCR (n = 8). (G) Kaplan-Meier survival curve of cancer-bearing mice treated with vehicle (n = 6) or Scl-Ab (n = 6). Data are presented as mean ± 
SEM. Two groups were compared using 2-tailed Student’s t test; *P < 0.05.
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TGF-β1 is an abundant growth factor released from the bone matrix during breast cancer–induced bone 
resorption. Interestingly, stimulation of  undifferentiated C2C12 myoblasts with TGF-β1 activated the p38/
NF-κB pathway, thus recapitulating the effect observed in muscles of  cancer-bearing mice (Figure 5B). Inhi-
bition of  the NF-κB pathway abrogated TGF-β1–induced phosphorylation of  p38 (Figure 5C), suggesting 
that the effect of  TGF-β1 was at least in part mediated via NF-κB. Consistently, TGF-β1 stimulation inhibit-
ed the differentiation of  C2C12 myoblasts into myocytes, as determined by reduced expression of  myogenin 
and MyoD (Figure 5D). These data suggest that TGF-β1 released from the bone matrix during osteolytic 
bone resorption reduces muscle function, which is prevented by Scl-Ab treatment. Indeed, expression of  the 
TGF-β1 target gene Pai1 was significantly increased in muscles of  bone metastasis–bearing mice compared 
with healthy animals (Figure 5E). However, Pai1 expression was not increased in the muscles of  Scl-Ab–
treated tumor-bearing mice (Figure 5E), indicating that Scl-Ab treatment restores the breast cancer-induced 
activation of  the TGF-β1 and p38/NF-κB pathway.
In colon cancer, NF-κB accumulation prevents the downregulation of  Pax7, leading to a com-
promised muscle regeneration and impaired skeletal muscle function (29). To address the question 
of  whether this also occurs in mice with breast cancer bone metastases, we analyzed the number of  
Pax7-positive satellite cells in the TA muscles. Interestingly, the number of  Pax7-positive cells was 
significantly increased in cancer-bearing mice compared with healthy animals (Figure 5, F and G). 
This cancer-induced increase was partially but significantly reversed by Scl-Ab treatment (Figure 5G). 
Together, these data suggest that pharmacological inhibition of  sclerostin protects from breast cancer–
induced loss of  muscle function by preventing the cancer-mediated activation of  NF-κB signaling and 
the subsequent increase in Pax7-positive satellite cells.
Discussion
In the present study, we report that MDA-MB-231 metastatic breast cancer cells secrete sclerostin, a soluble 
glycoprotein that binds to Lrp5/6 on osteoblasts and prevents the activation of  the Lrp5/6-frizzled receptor 
complex by soluble Wnt ligands and subsequent activation of  the canonical Wnt signaling pathway (11). In 
vitro assays revealed that metastatic breast cancer cell–derived sclerostin restricts osteoblast differentiation. 
In vivo inhibition of  sclerostin using a monoclonal anti-sclerostin antibody (Scl-Ab) reduced bone meta-
static burden and protected from breast cancer–induced bone destruction. At the tissue level, inhibition of  
sclerostin increased bone formation rate and bone mass in both healthy and cancer-bearing mice. In mice 
with bone metastases, sclerostin inhibition increased osteoblast number and bone formation rate, while 
the number and activity of  osteoclasts were decreased. Together these effects restricted tumor burden and 
osteolytic bone destruction, thereby increasing the survival time of  cancer-bearing mice.
Muscle weakness is known to accompany metastatic breast cancer disease (17, 30), which was con-
firmed in our model system. Interestingly, while Scl-Ab treatment did not affect the function of  healthy 
muscle, the decreased strength and endurance of  muscles obtained from mice with breast cancer bone 
metastases were reconstituted to the performance of  muscles obtained from healthy mice. At the tissue 
level, sclerostin inhibition restored the relative smaller size of  oxidative and nonoxidative muscle fibers in 
cancer-bearing mice. Molecularly, similar to the results found by stimulation with TGF-β1, metastatic bone 
disease activated p38/NF-κB signaling and increased the number of  Pax7-positive satellite cells in muscle 
tissue, which was largely abrogated by Scl-Ab treatment.
Figure 3. Anti-sclerostin antibody treatment protects from breast cancer–induced bone destruction. (A and B) Microcomputed tomography 
(μCT) analysis of bone mass (BV/TV, bone volume/total volume) of the femur (A) and tibia (B) of cancer-bearing mice treated with vehicle (n = 
8) or anti-sclerostin antibody (Scl-Ab; n = 8). (C) Von Kossa/van Gieson staining of proximal tibiae and fluorescence double labeling (insets) from 
healthy mice and cancer-bearing mice treated with vehicle or Scl-Ab. Scale bars: 1 mm (black) and 50 μm (white). (D) Histomorphometric analysis 
of bone mass (BV/TV, bone volume/tissue volume) of the proximal tibia (healthy nontreated n = 5, vehicle-treated n = 10, Scl-Ab–treated n = 10; 
cancer-bearing vehicle-treated n = 8, cancer-bearing Scl-Ab–treated n = 8). (E) Analysis of bone formation rate (BFR/BS, bone formation rate/bone 
surface) of the proximal tibia. (F) Von Kossa/van Gieson staining (2 left panels) of the proximal tibia of mice with bone metastases and calcein 
double labeling (2 right panels) at the bone-cancer interface. Scale bars: 50 μm. (G) BFR/BS at the bone-cancer interface (vehicle n = 6, Scl-Ab n 
= 3). (H) Immunohistochemical staining of osterix in the distal femur of cancer-bearing mice treated with vehicle or Scl-Ab. Scale bar: 50 μm. (I) 
Histomorphometric analysis of the distal femur (N.Ob/BS, number of osteoblasts per bone surface; Ob.S/BS, osteoblast surface per bone surface) 
(vehicle n = 6, Scl-Ab n = 3). (J) Tartrate-resistant acid phosphatase (TRAP) staining of the distal femur of cancer-bearing mice treated with vehicle 
or Scl-Ab. Scale bar: 50 μm. (K) Quantification of osteoclasts per bone surface (N.Oc/BS) and of the osteoclast surface per bone surface (Oc.S/BS) 
(vehicle n = 8, Scl-Ab n = 8). Data are presented as mean ± SEM. Two-tailed Student’s t test was used to compare 2 groups (A, B, G, I, and K), and 
ANOVA followed by Tukey’s post hoc analysis was used to compare 3 or more groups (D and E); *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 4. Inhibition of sclerostin prevents breast cancer–induced loss of muscle function. (A) Specific force of the extensor digitorum longus (EDL) 
muscle from healthy mice without treatment (n = 5), or treated with vehicle (n = 10) or anti-sclerostin antibody (Scl-Ab, n = 10); and from cancer-bearing 
mice treated with vehicle (n = 8) or Scl-Ab (n = 8). N, newtons. (B) Endurance of the EDL muscle of mice with bone metastases treated with vehicle (n = 
8) or Scl-Ab (n = 8). max, maximum. (C) Succinate dehydroxygenase–stained (SDH-stained) tibialis anterior muscle sections from healthy mice without 
treatment or with vehicle or Scl-Ab treatment, as well as from mice with bone metastases treated with vehicle or Scl-Ab stained. Two representative 
muscles are shown per group. Scale bar: 50 μm. (D) Quantification of the cross-sectional area (CSA) of all muscle fibers, oxidative fibers, and nonoxida-
tive fibers using SDH-stained muscle sections from healthy mice without treatment (n = 5), or with vehicle (n = 10) or Scl-Ab treatment (n = 10); and from 
cancer-bearing mice treated with vehicle (n = 8) or Scl-Ab (n = 8). Data are presented as mean ± SEM. Three or more groups were compared using ANOVA 
followed by Tukey’s post hoc analysis; *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 5. Treatment with an anti-sclerostin antibody reverses breast cancer–induced activation of NF-κB signaling and increased number of 
Pax7-positive cells. (A) Immunoblot analysis of phosphorylated IKKα and IKKβ (p-IKKα and p-IKKβ), phosphorylated NF-κBp65 (p-NF-κBp65), phos-
phorylated p38 (p-p38), and total p38 in the gastrocnemius (GAS) muscle of healthy nontreated mice (n = 5) and cancer-bearing mice treated with 
vehicle (n = 8) or Scl-Ab (n = 8). Actin was used as loading control. Representative samples are shown. (B) Immunoblot analysis of phosphorylated 
NF-κBp65 (p-NF-κBp65), phosphorylated p38 (p-p38) and total p38 in C2C12 myoblasts stimulated with vehicle (veh) or TGF-β1. Actin was used as 
loading control. Representative image of 6 independent experiments is shown. (C) Immunoblot analysis of phosphorylated NF-κBp65, p-p38, and 
total p38 in C2C12 cells treated with a control peptide or an NF-κB blocking peptide (NPD) and stimulated with vehicle or TGF-β1. Actin was used as 
loading control. Representative image of 4 independent experiments is shown. (D) Myogenin and MyoD mRNA expression was quantified by qRT-PCR 
in C2C12 cells after 10 days of myogenic differentiation (n = 4). (E) Pai1 mRNA expression was quantified in the GAS muscle from healthy nontreat-
ed mice (n = 5) and from cancer-bearing mice treated with vehicle (n = 8) or Scl-Ab (n = 8). (F) Immunohistochemical staining of Pax7 in the tibialis 
anterior (TA) muscle from healthy nontreated mice and from mice with bone metastases treated with vehicle or Scl-Ab. Scale bar: 50 μm (top row) 
and 100 μm (bottom row). (G) Quantification of Pax7-positive cells in the TA muscle from healthy nontreated mice (n = 5) and from mice with bone 
metastases treated with vehicle (n = 8) or Scl-Ab (n = 8). Data are presented as mean ± SEM. Two-tailed Student’s t test was used to compare 2 
groups (D), and ANOVA followed by Tukey’s post hoc analysis was used to compare 3 or more groups (E and G); *P < 0.05, ***P < 0.001.
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Breast cancer is a devastating disease of  high prevalence, with a great potential to metastasize to bone. 
Bone metastases cause osteolytic lesions that lead to pain, pathologic fractures, and muscle weakness (17, 
18). These conditions are accompanied by high morbidity and mortality and an overall reduced surviv-
al rate (8). Current treatments are effective in reducing the progression of  osteolytic lesions but do not 
reverse bone destruction or improve muscle weakness, demonstrating the need for additional therapeutic 
options. In breast cancer–induced bone disease, it is firmly established that breast cancer cells create a hos-
tile microenvironment by secreting soluble factors that increase the number and activity of  bone-resorbing 
osteoclasts that eventually cause bone destruction (5). While some secreted factors including interleuk-
ins directly activate osteoclasts, other factors such as PTHrP stimulate osteoblasts to secrete RANKL, 
which in turn augments osteoclast activity and bone resorption (5). The activated bone resorption releases 
matrix-derived growth factors such as TGF-β1 that enhance cancer cell proliferation and further activate 
osteoclast activity and bone resorption, thereby establishing a feed-forward loop (5). In this context, osteo-
blasts mainly assume a passive role as recipients and sources of  growth factors. However, recent evidence 
and data reported in this study also suggest an active role of  osteoblasts during the establishment and 
expansion of  multiple myeloma and breast cancer (27, 31). For instance, myeloma cells have been report-
ed to inhibit bone formation, which is relieved by Scl-Ab treatment (27, 31). In contrast to breast cancer 
cells, myeloma cells do not express sclerostin, and the inhibition of  bone formation is likely mediated 
by Dkk1 and other factors (27, 31). Thus, augmentation of  bone formation by Scl-Ab treatment is likely 
caused by antagonizing osteocyte-derived sclerostin.
In metastatic breast cancer, it was shown that sclerostin is derived from metastatic tissue in addition to osteo-
cytes (32). This is consistent with our findings showing that metastatic MDA-MB-231 breast cancer cells and 
several other triple-negative breast cancer cells express sclerostin, while nonmetastatic or hormone receptor–pos-
itive breast cancer cells do not express sclerostin. ER signaling has been shown to reduce sclerostin expression 
(33). Whether low sclerostin expression in ER-positive breast cancer cells is due to estrogen signaling remains to 
be elucidated. However, it is possible that the lack of the ER is permissive for sclerostin expression in aggressive 
triple-negative cells. In the present study, sclerostin expression was analyzed in a restricted number of prima-
ry breast cancer tissue biopsies. Thus, investigating the expression of sclerostin in a larger patient cohort and 
in bone metastases would be useful to determine whether sclerostin expression correlates with the hormone 
receptor status and bone metastatic burden. Nevertheless, our results suggest that sclerostin expression might be 
an important functional feature of malignancy in triple-negative breast cancer that is likely to contribute to the 
deregulation of the local metastatic microenvironment and potentially to distant effects of bone metastases. Tri-
ple-negative breast cancer represents approximately 10%–15% of all breast cancers, and patients have high risk 
of relapse and poor survival compared with those with breast cancers expressing hormone receptors or HER-2/
neu (34). The good prognosis of hormone receptor–positive and HER-2/neu–amplified tumors is largely due to 
advances made in targeted therapies, i.e., agents that interfere with hormone production/action or inhibit HER-
2/neu, respectively (35). Unfortunately, there are no targeted therapies recommended for triple-negative breast 
cancer, and the prevailing treatment remains to be standard chemotherapy. Thus, identification of sclerostin 
expression in a subset of triple-negative breast cancers might be of translational relevance for the development 
of improved treatment options.
Our experiments reveal that MDA-MB-231 metastatic breast cancer cell–derived sclerostin binds to 
Lrp5 on osteoblasts, leading to inhibition of  canonical Wnt signaling and osteoblast differentiation. By this 
mechanism, metastatic breast cancer cells are likely to suppress osteoblast activity and bone formation in 
vivo, a component that might contribute to metastatic bone destruction by favoring osteoclast-dependent 
bone resorption over osteoblast-mediated bone formation. In addition to augmenting osteoblast function 
and bone formation, sclerostin inhibition using Scl-Ab strongly reduced the osteoclast number and activity. 
These findings are consistent with phase II and III clinical trials in which postmenopausal women with 
osteoporosis were treated with an anti-sclerostin antibody to increase BMD (36, 37). The decline in bone 
resorption might be due to increased expression of  the Wnt target gene osteoprotegerin (OPG), which acts 
as a decoy receptor to RANKL and decreases the RANKL/OPG ratio and bone resorption (38). The dual 
osteoanabolic and antiresorptive effect most likely contributes to the increase in bone mass and to the atten-
uation of  bone destruction in the context of  the osteolytic disease. Indeed, Scl-Ab treatment of  mice bearing 
bone metastases greatly reduced the metastatic burden compared with vehicle-treated mice. Reduction of  
bone metastases did not increase metastasis formation at other sites, leading to a decrease in overall meta-
static burden. Importantly, Scl-Ab treatment of  metastasis-bearing mice prolonged overall survival.
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Patients with advanced metastatic breast cancer often experience a wasting condition in which skel-
etal muscle undergoes atrophy, leading to pronounced weight loss and ultimately cachexia (39, 40). In 
the muscle microenvironment, Pax7-positive satellite cells are the main resident stem cells that can give 
rise to myocytes (41). In addition, other interstitial and perivascular cell populations can also enter the 
myogenic lineage and contribute to muscle repair in response to tissue damage (42). Muscle damage can 
be a consequence of  cachexia that is associated with an expansion and activation of  Pax7-positive inter-
stitial satellite cells and type 2 fiber atrophy (43). Satellite cell activation is indicated by an increased 
abundance of  desmin and phospho-p38α (44). Under normal conditions, satellite cells are positioned 
between the myofiber sarcolemma and the basal lamina, but exit from quiescence upon muscle damage 
along with other myogenic progenitor populations and subsequently expand as myoblasts to repair 
damaged fibers (45). Perturbation of  the sarcolemma and the basal lamina as well as satellite cell acti-
vation in cachectic muscle is not due to the spreading of  tumor cells but rather caused by circulating 
factors including TGF-β1 (17). Serum-derived cachectic factors activate NF-κB signaling in myogenic 
progenitors upstream of  Pax7, which becomes upregulated and suppresses expression of  MyoD and 
myogenin. This mechanism blocks myogenic differentiation and myoblast fusion and promotes muscle 
wasting (29). Furthermore, it has been demonstrated that the increase in circulating TGF-β1 in the 
context of  osteolytic disease upregulated NADPH oxidase 4 in skeletal muscle, causing an oxidation 
of  the ryanodine receptor and calcium (Ca2+) release channel (RyR1) (17). Oxidation of  RyR1 leads to 
Ca2+ leakage and an impairment of  muscle contraction (17). These findings strongly indicate that sev-
eral molecular mechanisms exist that contribute to a cancer- and bone metastasis–mediated decline in 
muscle function and ultimately cachexia.
In the present study, we report that mice with breast cancer bone metastases have reduced muscle 
strength and endurance and demonstrate that the muscle weakness is fully abrogated by treatment with 
Scl-Ab. Our data are consistent with findings reported by others and demonstrate that advanced stages 
of  malignancy and bone metastases cause muscle weakness (17). However, the use of  Scl-Ab to improve 
muscle function has not to our knowledge been reported thus far but would be of  great clinical interest. 
At the tissue level, advanced malignancy with bone metastases caused a reduction in the size of  oxi-
dative and nonoxidative muscle fibers. Antagonizing sclerostin activity reversed muscle fiber atrophy, 
thereby normalizing the tissue microarchitecture. Molecularly, cancer-induced muscle fiber atrophy was 
associated with increased NF-κB and p38 signaling that was also induced by TGF-β1 and normalized 
by Scl-Ab treatment. Stimulation with TGF-β1 also reduced myogenin expression and myoblast dif-
ferentiation. These findings suggest that enhanced osteoclast activity in the bone cancer microenvi-
ronment increases the serum concentration of  bone matrix–derived TGF-β1, and impairs myogenin 
expression and muscle regeneration downstream of  NF-κB and p38 signaling. Indeed, TGF-β1 path-
way activity was increased in muscle tissue as evidenced by increased Pai-1 expression, which was at 
least in part reconstituted by sclerostin inhibition. Furthermore, the number of  Pax7-positive satellite 
cells was strikingly increased in tumor-bearing mice and almost normalized by Scl-Ab treatment. We 
therefore propose that the bone-forming effect and antiresorptive properties of  anti-sclerostin treatment 
both contribute to a reduction in osteolytic bone destruction and extension of  survival time, while the 
anticatabolic effect mainly contributes to restoration of  muscle function by preventing an increase in 
TGF-β1 concentration.
Consistent with other reports, we demonstrated that Scl-Ab treatment has a bone-sparing effect 
and reduces bone destruction in the context of  a malignant bone disease that disturbs the balance of  
the bone microenvironment. Muscle fiber atrophy and muscle weakness, which often accompany met-
astatic breast cancer, were also prevented by pharmacological inhibition of  sclerostin. These features 
are clinically relevant and may improve the current treatment options for patients with breast cancer 
bone metastases. In all preclinical and clinical studies that are available thus far, Scl-Ab treatment has 
been proven safe with regard to malignant side effects. Its clinical use might therefore be possible even 
with a history of  a malignant disease or an actual cancer diagnosis, which is a great advantage over 
the currently available bone-anabolic drugs PTH 1-34 (teriparatide; Forteo/Forsteo, Eli Lilly and Co.) 
and PTHrP (abaloparatide; Tymlos, Radius) (6). It would therefore be of  great interest to investigate, 
in a clinical context, whether sclerostin inhibition is also beneficial for patients with breast cancer bone 
metastases. This would expand the repertoire of  oncological treatment options for and improve the 
bone health of  breast cancer patients.
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Methods
Animal experiments. MDA-MB-231 breast cancer cells stably expressing the luciferase have been described else-
where (46) and were injected into the left ventricle of 8-week-old female immune-compromised CB-17/lcr-Prk-
dcscid/Rj mice (Janvier Laboratories). Bioluminescence imaging (BLI) was performed 2 weeks after breast can-
cer cell injection using an IVIS 200 imaging system (PerkinElmer), and mice were randomized into 2 treatment 
arms. One group (n = 8) received vehicle (50 μl/10 g mouse), and the other group (n = 8) Scl-Ab (100 mg/kg; 
BPS-804, setrusumab; Mereo BioPharma) i.v. once a week for 4 weeks. Tumor burden was measured weekly 
by BLI. Mice were sacrificed 1 week after the last injection. In the survival study, mice were treated once a 
week with vehicle (n = 6) or Scl-Ab (n = 6), monitored daily, and sacrificed once well-defined criteria such as 
20% weight loss were reached. Healthy CB-17/lcr-Prkdcscid/Rj mice without treatment (n = 10), or treated with 
vehicle (n = 10) or Scl-Ab (n = 10) served as controls. Investigators were blinded to the group allocation.
μCT. μCT was used for 3D analyses of  long bones. Long bones of  mice were analyzed using high-res-
olution μCT with a fixed isotropic voxel size of  10 μm (70 peak kV at X μA 400 ms integration time; 
Viva80 microCT; Scanco Medical). All analyses were performed on digitally extracted bone tissue using 
3D distance techniques (Scanco Medical) as reported previously (47). Region of  interest (ROI) was defined 
manually by drawing contours in slices. Due to cancer-induced bone destruction and absence of  intact 
bone surfaces in cancer-bearing mice, the ROI contained both cortical and the trabecular bone. In non-can-
cer-bearing bones, only trabecular bone was analyzed using a standard method (47).
Ex vivo analysis of  muscle function. Ex vivo contractility of  EDL muscle was analyzed using a device 
dedicated to the measurement of  mouse muscle properties in situ, ex vivo, and in vivo (Aurora Scientific). 
For this purpose, EDL was dissected from the hind limb, loops were tied to the tendons of  the muscles, 
and mounted to a force transducer. Muscles were stimulated to contract using a supramaximal stimulus 
applied by 2 electrodes. For fatigue studies, EDL was stimulated with 70 Hz for 50 repeats, and the maxi-
mum tetanic force was detected. Data were collected and analyzed using Dynamic Muscle Control/Data 
Acquisition (DMC) and Dynamic Muscle Control Data Analysis (DMA) programs (Aurora Scientific). 
Specific muscle force was calculated as described previously (48). Investigators were blinded regarding the 
treatment during data analysis.
Histological and immunohistochemical analyses. For bone analyses, mice were injected 7 and 2 days prior to 
sacrifice with calcein (20 mg/kg) and demeclocycline (20 mg/kg; both Sigma-Aldrich), respectively. Tibiae 
were collected and fixed in 4% paraformaldehyde (PFA) for 48 hours. For histomorphometric analysis, tibi-
ae were embedded in methyl methacrylate. Toluidine blue, von Kossa/van Gieson and TRAP staining were 
performed using 5-μm sagittal sections. Quantitative bone histomorphometric measurements were performed 
according to standard protocols using an OsteoMeasure system (Osteometrics) (49). Femurs were cleaned from 
soft tissue, fixed in 4% PFA for 24 hours at 4°C, decalcified with 4% EDTA for 4 days and 20% EDTA for 24 
hours, and embedded in paraffin. Sections were cut, and immunohistochemical staining was performed using 
an anti-Osterix antibody (rabbit polyclonal; Santa Cruz Biotechnology). Brain and lung tissues were fixed in 
4% PFA for 24 hours at 4°C. Tissue samples were embedded in paraffin and cut, and immunohistochemical 
staining was performed with an antibody against HLA class 1 ABC (mouse monoclonal, Abcam).
For histological analyses of  muscle tissues, the TA muscle was dissected from the hind limb, embedded 
in 10% Gum Tragacanth, and snap-frozen in cooled 2-methylbutane. Cryosections were prepared using a 
cryotome, and sections were stained for succinate dehydroxygenase (SDH). Pax7 staining was performed 
using an anti-Pax7 antibody (mouse monoclonal; Developmental Studies Hybridoma Bank [DSHB]). Mus-
cle fiber area and number of  Pax7-positive cells were quantified using the Osteomeasure system (Osteomet-
rics). The investigators were blinded regarding the treatment.
Cell culture. For calvarial osteoblast cultures, calvariae were dissected from 1- to 3-day-old mice and 
digested sequentially in α-MEM containing 0.1% collagenase and 0.2% dispase (both Roche). Cell frac-
tions 2–4 were combined and expanded in α-MEM (Invitrogen) containing 10% FBS (Invitrogen) and 100 
U/ml penicillin, 100 μg/ml streptomycin (Invitrogen). C2C12 cells were purchased from DSMZ and cul-
tured in DMEM (Invitrogen) containing 10% FBS and 1% penicillin/streptomycin. Cells were stimulated 
with 10 ng/ml TGF-β1 (R&D Systems) or 100 ng/ml recombinant sclerostin (R&D Systems). To inhibit 
NF-κB signaling in C2C12 cells, cells were pretreated for 1 hour with NEMO-binding domain peptide 
(NPD, Enzo) or L-TAT control peptide (Enzo). Myocyte differentiation was induced using DMEM sup-
plemented with 2% horse serum (Invitrogen) and 1% penicillin/streptomycin. MCF-7 and MDA-MB-231 
breast cancer cells were purchased from ATCC. MCF-7 cells were cultured in DMEM (Invitrogen), and 
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MDA-MB-231 cells were grown in α-MEM, both supplemented with 10% FBS and 1% penicillin/strep-
tomycin. All cell lines were tested for mycoplasma contamination. MDA-MB-231 cells were transfected 
with scrambled control siRNA or siRNA against sclerostin (Origene) using Lipofectamine 3000 (Thermo 
Fisher Scientific) according to the manufacturer’s instructions. For collection of  conditioned medium, 
MDA-MB-231 cells were cultured in the presence of  1% FBS for 24 hours, and conditioned medium was 
collected and stored at –80°C. Osteoblast differentiation was induced by supplementing α-MEM with 
0.2 mM l-ascorbic acid and 10 mM β-glycerophosphate (both Millipore). Osteoblast differentiation was 
determined by staining the cells with 40 mM alizarin red S (AR-S; Sigma-Aldrich) solution at pH 4.2 for 
10 minutes at room temperature after fixing the cells in 4% neutrally buffered formaldehyde solution. 
To determine Wnt signaling activity, calvarial osteoblasts were transfected with TOPflash and Renilla 
plasmids using the Neon System (Invitrogen). Luciferase activity was measured using the Promega Dual 
Luciferase kit following the manufacturer’s guidelines.
RNA isolation and qRT-PCR. Lung and brain tissues were snap-frozen in liquid nitrogen, and RNA was 
isolated using Trizol. RNA was isolated from cultured cells using the RNeasy Plus Mini Kit (QIAGEN). 
cDNA was synthesized using the NEB ProtoScript II First Strand cDNA Synthesis kit according to the 
manufacturer’s instructions. Expression of  myogenin, MyoD, Pai1, SOST, and the human leukocyte antigen 
(HLA) gene was quantified by qRT-PCR. After normalization to GAPDH mRNA, the relative expression 
level of  each target gene was calculated using the comparative CT method.
Expression analysis in human tissue. SOST expression in 48 human breast cancer tissues was analyzed using 
the TissueScan Breast Cancer Array III (Origene) according to the manufacturer’s instructions. TissueScan 
Cancer Survey Array 96 I (Origene), consisting of 72 tumor samples and 24 nonmalignant tissue samples from 
8 different primary organs, was utilized to analyze the expression pattern of SOST in various malignant tissues. 
Expression of SOST was quantified using qRT-PCR. Beta-actin (ACTB) was used as an internal control.
Immunoblotting. Cells were lysed in low-salt lysis buffer (pH 7.6) containing 50 mM Tris base, 150 mM NaCl, 
0,5% Nonindet P-40 (NP-40), 0.25% sodium deoxycholate, and complete protease and phosphatase inhibitors 
(Roche). Muscle tissue was homogenized in lysis buffer (20 mM Tris, pH 7.8, 137 mM NaCl, 2.7 mM KCl, 1 
mM MgCl2, 1% Triton X-100, 10% glycerol, 1 mM EDTA, 1 mM dithiothreitol, and protease and phosphatase 
inhibitors) using a Dounce homogenizer. Lysates were separated on 12% polyacrylamide gels and subjected to 
immunoblot analysis. Immunoblots were incubated overnight at 4°C with primary antibodies listed in Table 2. 
Peroxidase-labeled anti-rabbit or anti-mouse secondary antibodies (1:10,000, Santa Cruz Biotechnology, catalog 
Table 2. Antibodies used in this study
Antibody Host animal Dilution Source Catalog no. Application
Pax7 Mouse 1:10 DSHB – IHC
HLA Mouse 1:100 Abcam ab70328 IHC
Osterix Rabbit 1:500 Santa Cruz 
Biotechnology
Sc-22536-R IHC
p38 Rabbit 1:500 Cell Signaling 
Technology
8690 IB
Phospho-p38 Rabbit 1:500 Cell Signaling 
Technology
4511 IB
Phospho-IKKα Rabbit 1:500 Elabscience E-AB-20902 IB
Phospho-IKKβ Rabbit 1:500 Elabscience E-AB-20903 IB
Phospho–NF-κB p65 Rabbit 1:500 Abcam ab28856 IB
Actin Mouse 1:5000 Millipore MAB1501 IB





Rabbit 1:1000 Cell Signaling 
Technology
4370 IB
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W401B, W402B) were used to visualize bands using Clarity Western ECL Substrate (Bio-Rad). Images of the 
immunoblots were acquired using the ChemiDoc imaging system and Image Lab software (Bio-Rad).
ELISA. ELISA was used to determine P1NP and TRAP concentration in mouse serum. All procedures 
were performed according to the manufacturer’s (immunodiagnostics systems) instructions.
Statistics. Parametric data were analyzed using 2-tailed Student’s t test when 2 groups were compared. 
ANOVA was used when more than 2 groups were compared, followed by Tukey’s post hoc analysis to com-
pare the groups. Probability values were considered statistically significant at P < 0.05. Experiments were 
repeated at least 3 times as biological replicates, with a minimum of  2 technical replicates. All quantitative 
data are presented as mean ± SEM.
Study approval. All animal experiments were conducted in compliance with ethical regulations and 
according to protocols approved by the local authority for animal welfare (Behörde für Gesundheit und 
Verbraucherschutz [BVG], Hamburg, Germany).
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